Spinal Cord Series and Cases, 2017 · DOI: 10.1038/scsandc.2017.19 · Published: May 11, 2017
This case report discusses the use of a novel antibiotic combination, ceftolozane/tazobactam (C/T), to treat a complicated urinary tract infection (UTI) in a patient with a neurogenic bladder caused by multidrug-resistant Pseudomonas aeruginosa (PSA). The patient had a spinal cord injury and the infection was resistant to many antibiotics. The patient was treated with C/T after initial treatment with other antibiotics. The patient responded well to C/T, showing no signs of infection and negative urine cultures within a month. The report suggests that C/T may be a safe and effective option for treating febrile UTIs caused by MDR PSA in spinal cord injury patients with neurogenic bladders, even when used alone.
Ceftolozane/tazobactam could be considered as a treatment option for MDR Pseudomonas aeruginosa infections in patients with neurogenic bladder.
The case suggests that ceftolozane/tazobactam monotherapy may be effective in certain cases, potentially reducing the need for combination therapy and its associated risks.
Controlled studies are needed to confirm the efficacy and safety of ceftolozane/tazobactam in this specific patient population.